Compare MGM Resorts International (MGM) vs Summit Therapeutics Inc (SMMT) Price & Performance

MGM Resorts International (MGM) stock is trading at $29.27, down 2.43% on the day and reflecting significant pressure following the collapse of Barry Diller's $48.30 per share acquisition proposal in late September 2026. The technical picture is bearish, while fundamentals show mixed signals with revenue growth to $17.54B in 2025 but declining net income margins. Analyst sentiment remains predominantly positive with a consensus price target of $48.75, suggesting substantial upside potential from current levels.

The investment case hinges on MGM's ability to execute its strategic initiatives and potentially pursue acquisitions like People Inc. to unlock value. Near-term risks include integration challenges, market volatility, and execution missteps. The current valuation at a P/E of 18.19 and P/S of 0.45 appears reasonable if management can stabilize profitability and navigate the post-deal uncertainty.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.